INTRODUCTION: Endoscopic biliary sphincterotomy has just enjoyed its 25th anniversary, but endoscopic pancreatic sphincterotomy (EPS) has been performed for less than 10 years with little long-term follow-up data. We employ only pull-type EPS, and have described a safe, stentless technique (Gastrointestinal Endosc 1998;47:240-9). We report our long-term results. PATIENTS & METHODS: From 1/91 to 10/99, we performed 397 EPS procedures on 349 patients. There were 144 males, 205 females, age 5 to 90. The indications for sphincterotomy were SOD, recurrent acute pancreatitis, chronic pancreatitis, pancreatic duct stones, ampullary polypectomy, pancreatic fistula, and pseudocyst drainage. 238 EPS (60%) had nasopancreatic drainage, 132 (33%) were accompanied by PD stent placement, and 27 (7%) had no drainage. 332 (84%) EPS were of the major papilla in 293 patients and 65 (16%) were of the minor papilla performed in 56 patients. 10 patients had both major and minor duct sphincterotomies on different occasions. Follow-up has been for a median of 34 months with a minimum follow-up of 6 months. RESULTS: There were 22/397 (5%) shortterm complications consisting of mild pancreatitis (N=13), mild or moderate bleeding (N=2), mild perforation (N=2), cholangitis, stent migration, pain relieved by stent removal, and premature patient removal of a nasopancreatic drain (N=1 each). There were no requirements for surgery and no deaths. Long-Term Follow-Up: 39 of 397 (10%) EPS were repeat sphincterotomies performed in 34 patients for incomplete initial EPS (n=4), for additional therapies, such as stone removal, ampullary polypectomy or pseudocyst drainage (n=19), and for restenosis with recurrent symptoms (n=16). In these last 16 (4%), 6 were minor duct EPS (6/65=9.2%) compared to 10 major duct EPS (10/332=3%; p=0.03). Of the 16, 7 had underlying chronic pancreatitis characterized by ongoing disease and inflammation. There was only 1 complication in the repeat EPS group comprising minor bleeding after EPS extension to remove a migrated PD stent. IMPRESSION: Our previously described technique of pull-type pancreatic sphincterotomy is both safe and effective in moderate to long-term follow-up.We employ nasopancreatic drainage to avoid the risks and costs of pancreatic stenting when post sphincterotomy drainage beyond 24 hours is not anticipated. There is a very low incidence of restenosis. Minor duct sphincterotomy is more likely to restricture compared to major duct EPS. INTRODUCTION: Endoscopic biliary sphincterotomy has just enjoyed its 25th anniversary, but endoscopic pancreatic sphincterotomy (EPS) has been performed for less than 10 years with little long-term follow-up data. We employ only pull-type EPS, and have described a safe, stentless technique (Gastrointestinal Endosc 1998;47:240-9). We report our long-term results. PATIENTS & METHODS: From 1/91 to 10/99, we performed 397 EPS procedures on 349 patients. There were 144 males, 205 females, age 5 to 90. The indications for sphincterotomy were SOD, recurrent acute pancreatitis, chronic pancreatitis, pancreatic duct stones, ampullary polypectomy, pancreatic fistula, and pseudocyst drainage. 238 EPS (60%) had nasopancreatic drainage, 132 (33%) were accompanied by PD stent placement, and 27 (7%) had no drainage. 332 (84%) EPS were of the major papilla in 293 patients and 65 (16%) were of the minor papilla performed in 56 patients. 10 patients had both major and minor duct sphincterotomies on different occasions. Follow-up has been for a median of 34 months with a minimum follow-up of 6 months. RESULTS: There were 22/397 (5%) shortterm complications consisting of mild pancreatitis (N=13), mild or moderate bleeding (N=2), mild perforation (N=2), cholangitis, stent migration, pain relieved by stent removal, and premature patient removal of a nasopancreatic drain (N=1 each). There were no requirements for surgery and no deaths. Long-Term Follow-Up: 39 of 397 (10%) EPS were repeat sphincterotomies performed in 34 patients for incomplete initial EPS (n=4), for additional therapies, such as stone removal, ampullary polypectomy or pseudocyst drainage (n=19), and for restenosis with recurrent symptoms (n=16). In these last 16 (4%), 6 were minor duct EPS (6/65=9.2%) compared to 10 major duct EPS (10/332=3%; p=0.03). Of the 16, 7 had underlying chronic pancreatitis characterized by ongoing disease and inflammation. There was only 1 complication in the repeat EPS group comprising minor bleeding after EPS extension to remove a migrated PD stent. IMPRESSION: Our previously described technique of pull-type pancreatic sphincterotomy is both safe and effective in moderate to long-term follow-up.We employ nasopancreatic drainage to avoid the risks and costs of pancreatic stenting when post sphincterotomy drainage beyond 24 hours is not anticipated. There is a very low incidence of restenosis. Minor duct sphincterotomy is more likely to restricture compared to major duct EPS.